TransCode closes $8.5M public offering; issues 16.9M shares/pre-funded warrants at $0.51

Transcode Therapeutics, Inc.

Gross proceeds ~$8.5M from sale of 700K common shares and 16.2M pre-funded warrants at $0.51 per share/warrant, including partial over-allotment exercise.
Use of proceeds for clinical trials of lead candidate TTX-MC138 and working capital.
ThinkEquity sole book-runner; granted 45-day over-allotment option (partially exercised) plus 843K underwriter warrants at $0.6375 per share.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Transcode Therapeutics, Inc. entered into Underwriting Agreement with ThinkEquity LLC valued at approximately $8.5 million (effective 2023-09-25).

Action: entry
Agreement: underwriting
Counterparty: ThinkEquity LLC
Value: approximately $8.5 million
Effective: 2023-09-25

Exact text from the filing

On September 25, 2023, TransCode Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with ThinkEquity LLC, as underwriter (the “Underwriter”), pursuant to which the Company agreed to issue and sell, in a public offering (the “Offering”), an aggregate of (i) 700,000 shares (“Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and (ii) pre-funded warrants (“Pre-Funded Warrants”) to purchase 16,163,000 shares of Common Stock

View on SEC.gov

119 material agreements filed in the last 30 days. Browse all material agreements →

Transcode Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-104743

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.